Importing a Chinese plasma product is really two questions: first, whether China will export it (covered here), and second, whether your country will import it. This page is about the second question. The good news is that the second question follows a consistent shape in nearly every market; the details are what change.
The universal pattern
Whatever the destination, a legitimate import runs through the same sequence. Skip a step and the application stalls — usually at the same place, for the same reason.
| Step | What happens | Who does it |
|---|---|---|
| 1. Confirm exportability | Product is finished, registered, batch-released — not source plasma | Exporter + manufacturer |
| 2. Confirm importability | Your market allows this product class at all | Importer + local regulator |
| 3. Assemble the dossier | CPP, approval number, batch release, GMP, CoA, export mandate | Exporter provides; importer adapts |
| 4. Local registration | File with the importing country's authority, through a local holder or agent | Local agent / holder |
| 5. Import & release | Ship, then the importing authority releases the batch for use | Importer + local authority |
The documents every authority asks for
The core file is remarkably consistent across markets. What differs is language, format and whether the authority wants original or legalised copies.
- Certificate of Pharmaceutical Product — the registration and marketing-status evidence.
- The drug approval number, verifiable on the NMPA database.
- The batch release certificate — that the specific lot was state-released.
- GMP evidence for the manufacturing site.
- A certificate of analysis for the specific batch.
- The export mandate or authorisation naming the exporter.
Market-by-market notes
The following are working notes on the markets buyers most often ask about. They describe the shape of the path, not a filing checklist — every authority has its own forms and fees, and requirements change.
| Market | What to expect |
|---|---|
| India | Import of blood products requires registration through the national drug regulator, with local testing and a local agent. Plasma-derived products face scrutiny around the source plasma and batch release documentation. |
| Pakistan | Registration via the Drug Regulatory Authority, dossier-based, with the CPP and GMP evidence central. A local authorised importer is required. |
| Brazil | A mature, inspection-driven authority (ANVISA). Registration typically requires GMP inspection or recognition, plus the full product file. Boya's IVIG has prior supply history here. |
| Singapore | Reference-agency recognition and a compact dossier. Singapore accepts well-documented registrations and is comparatively fast for products with strong reference-country approval. |
| Middle East | A bloc of separate authorities (Saudi SFDA, UAE, GCC). Registration is per country, usually dossier-based with the CPP, GMP and batch release as the backbone. |
Two cross-cutting cautions. First, several countries restrict or prohibit the import of plasma-derived products regardless of registration — a policy question to settle before spending on a dossier. Second, legalisation and translation are the silent time sinks: a dossier that is complete but not legalised or not in the required language stalls the same as an incomplete one.
The cheapest question in market entry is "does your market import this product class at all?" Ask it before assembling a single document.
How this connects to the product file
Market entry is where the earlier checks pay off. A verified approval number, a real batch release and a clean CPP mean the dossier does not fall over at the authority's first review. The supplier checks in the due-diligence checklist are what protect you before you spend on registration.
Frequently asked questions
What is the first step to import a Chinese blood product?
Confirm the product is a finished, registered product that China actually exports — never source plasma, which is export-prohibited. Then confirm your own country's registration and import requirements, which are separate from China's rules.
Do I need a local registration in the importing country?
Almost always yes. The importing country typically requires the product to be registered locally, supported by documents such as the Certificate of Pharmaceutical Product, the batch release certificate and GMP evidence. Registration is done through a local holder or agent.
How long does it take to register a product in a new market?
It varies by market and product class. Some markets take months for a dossier-based registration; others take a year or more and may require local testing or inspection. The dossier preparation is often the longest single block.
What documents does the importing authority usually ask for?
Typically the Certificate of Pharmaceutical Product, the drug approval number and its verification, the batch release certificate, GMP evidence, a certificate of analysis, and an export mandate or authorisation from the marketing authorisation holder.
Can the same dossier be reused across several countries?
Partly. The core product file — approval number, CPP, batch release, GMP — is reusable, but each market has its own forms, language requirements and sometimes its own testing, so the dossier must be adapted per destination rather than filed once.
Where to go next
- China import & export regulations — the export-side rules this guide assumes.
- Certificate of Pharmaceutical Product — the document every dossier turns on.
- Open territories — where we are actively appointing partners, product by product.